Coutinho Anna D, Raju Aditya D, Wang Weijia, Stafkey-Mailey Dana, Shetty Sharash, Sander Stephen D
a Xcenda LLC , Palm Harbor , FL , USA.
b Boehringer Ingelheim Pharmaceuticals Inc. , Ridgefield , CT , USA.
Curr Med Res Opin. 2018 Jun;34(6):1005-1012. doi: 10.1080/03007995.2018.1434497. Epub 2018 Feb 16.
To evaluate the incremental economic burden of type 2 diabetes in patients experiencing cardiovascular (CV) hospitalizations.
Adults with ≥1 CV hospitalization were identified using a US-based healthcare claims database from 1 July 2011 to 30 June 2014. Outcomes for patients surviving the index hospitalization were compared between patients with vs. without type 2 diabetes (cohorts were identified in the pre-index period). Subsequent CV hospitalizations were evaluated using Cox proportional hazards models. All-cause and CV-related healthcare resource utilization (HCRU) and costs captured on a per-patient per-month (PPPM) basis during a variable follow-up period were evaluated using appropriate multivariable regression models.
Of 316,207 patients with ≥1 CV hospitalization, 23% had comorbid type 2 diabetes. The mean age ± SD was 62.6 ± 12.3 years and 64.4% were male. During follow-up, the type 2 diabetes cohort had a 19% higher risk of subsequent CV hospitalizations compared to the non-type-2-diabetes cohort (p < .001). This difference in risk was highest in patients aged 35-44 years. Subsequent all-cause hospitalizations for the type 2 diabetes cohort were longer (mean length of stay, 6.7 vs. 6.3 days; p < .001), with higher total bed-days PPPM (mean, 0.52 vs. 0.43; p < .001), compared to the non-type-2-diabetes cohort. The type 2 diabetes cohort had a significantly higher incremental cost for both the index CV hospitalization (mean cost difference, $1046; p < .001) and all-cause costs PPPM following discharge (mean cost difference, $749; p < .001).
Comorbid type 2 diabetes was associated with an increased risk of subsequent CV hospitalizations and higher costs and HCRU during the follow-up period.
评估心血管疾病(CV)住院患者中2型糖尿病的额外经济负担。
使用美国医疗保健索赔数据库,确定2011年7月1日至2014年6月30日期间至少有1次CV住院治疗的成年人。比较指数住院治疗存活患者中患2型糖尿病与未患2型糖尿病患者的结局(队列在指数前期确定)。使用Cox比例风险模型评估后续的CV住院治疗。在可变的随访期内,使用适当的多变量回归模型评估以每位患者每月(PPPM)为基础的全因和CV相关医疗资源利用(HCRU)及成本。
在316,207例至少有1次CV住院治疗的患者中,23%患有2型糖尿病合并症。平均年龄±标准差为62.6±12.3岁,64.4%为男性。在随访期间,2型糖尿病队列后续CV住院的风险比非2型糖尿病队列高19%(p < 0.001)。这种风险差异在35 - 44岁的患者中最高。与非2型糖尿病队列相比,2型糖尿病队列的后续全因住院时间更长(平均住院时间,6.7天对6.3天;p < 0.001),PPPM总住院天数更高(平均,0.52对0.43;p < 0.001)。2型糖尿病队列在指数CV住院治疗(平均成本差异,1046美元;p < 0.001)和出院后的全因成本PPPM(平均成本差异,749美元;p < 0.001)方面均有显著更高的增量成本。
2型糖尿病合并症与后续CV住院风险增加以及随访期间更高的成本和HCRU相关。